LRRK2-in-1 specifically reduces the exacerbated vulnerability profile of mutant LRRK2 (p < 0.05) and highly sensitive sporadic PD patient lines (p < 0.05) to valinomycin (Fig. 1a). Here, LRRK2 is linked to Parkinson disease.